NasdaqCM:KIN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.


Similar Companies

Share Price & News

How has Kindred Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: KIN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.2%

KIN

-1.2%

US Biotechs

0.4%

US Market


1 Year Return

-52.3%

KIN

32.5%

US Biotechs

17.8%

US Market

Return vs Industry: KIN underperformed the US Biotechs industry which returned 32.5% over the past year.

Return vs Market: KIN underperformed the US Market which returned 17.8% over the past year.


Shareholder returns

KINIndustryMarket
7 Day-2.2%-1.2%0.4%
30 Day-9.2%2.3%6.1%
90 Day16.0%-2.6%8.9%
1 Year-52.3%-52.3%34.7%32.5%20.5%17.8%
3 Year-44.0%-44.0%20.0%14.0%42.3%32.9%
5 Year-24.3%-24.3%11.5%3.4%84.2%63.4%

Price Volatility Vs. Market

How volatile is Kindred Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Kindred Biosciences undervalued compared to its fair value and its price relative to the market?

1.84x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate KIN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate KIN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: KIN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: KIN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KIN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KIN is good value based on its PB Ratio (1.8x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Kindred Biosciences forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

29.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KIN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KIN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KIN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KIN's revenue (34.6% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: KIN's revenue (34.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if KIN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Kindred Biosciences performed over the past 5 years?

-20.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: KIN is currently unprofitable.

Growing Profit Margin: KIN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: KIN is unprofitable, and losses have increased over the past 5 years at a rate of 20.7% per year.

Accelerating Growth: Unable to compare KIN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KIN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).


Return on Equity

High ROE: KIN has a negative Return on Equity (-34.26%), as it is currently unprofitable.


Next Steps

Financial Health

How is Kindred Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: KIN's short term assets ($72.8M) exceed its short term liabilities ($6.9M).

Long Term Liabilities: KIN's short term assets ($72.8M) exceed its long term liabilities ($22.2M).


Debt to Equity History and Analysis

Debt Level: KIN's debt to equity ratio (22.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if KIN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KIN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: KIN has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 23.3% each year


Next Steps

Dividend

What is Kindred Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate KIN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KIN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KIN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KIN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KIN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.6yrs

Average management tenure


CEO

Richard Chin (53 yo)

8yrs

Tenure

US$3,593,388

Compensation

Dr. Richard Chin, M.D. serves as President at Kindred Biosciences, Inc. since July 31, 2020. Dr. Chin is a Co-Founder of Kindred Biosciences, Inc. and has been its Chief Executive Officer since October 201 ...


CEO Compensation Analysis

Compensation vs Market: Richard's total compensation ($USD3.59M) is above average for companies of similar size in the US market ($USD1.23M).

Compensation vs Earnings: Richard's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Richard Chin
Co-Founder8yrsUS$3.59m5.09%
$ 8.1m
Denise Bevers
Co-Founder & Director2yrsUS$1.46m0.37%
$ 584.0k
Wendy Wee
CFO & Secretary3.25yrsUS$987.87k0.11%
$ 179.1k
Hangjun Zhan
Chief Scientific Officer2.75yrsUS$982.70k0.094%
$ 150.1k
Katja Buhrer
Chief of Staffno datano datano data

5.6yrs

Average Tenure

56.5yo

Average Age

Experienced Management: KIN's management team is seasoned and experienced (5.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Richard Chin
Co-Founder8yrsUS$3.59m5.09%
$ 8.1m
Denise Bevers
Co-Founder & Director2yrsUS$1.46m0.37%
$ 584.0k
Herbert Montgomery
Independent Director4.5yrsUS$266.70k0%
$ 0
Ernest Mario
Independent Director2.5yrsUS$253.75k0.43%
$ 686.1k
Joseph S. McCracken
Independent Director2.5yrsUS$251.16k0%
$ 0
Ervin Veszprémi
Independent Director7.67yrsUS$258.93k0%
$ 0
Raymond Townsend
Independent Director6.92yrsUS$258.93k0.063%
$ 101.2k

4.5yrs

Average Tenure

67yo

Average Age

Experienced Board: KIN's board of directors are considered experienced (4.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Kindred Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kindred Biosciences, Inc.
  • Ticker: KIN
  • Exchange: NasdaqCM
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$159.836m
  • Shares outstanding: 39.37m
  • Website: https://www.kindredbio.com

Number of Employees


Location

  • Kindred Biosciences, Inc.
  • 1555 Bayshore Highway
  • Suite 200
  • Burlingame
  • California
  • 94010
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KINNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDDec 2013
17KDB (Deutsche Boerse AG)YesCommon StockDEEURDec 2013

Biography

Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic clas ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 05:14
End of Day Share Price2020/10/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.